Q2 2024 EPS Estimates for Pfizer Inc. Boosted by Analyst (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Investment analysts at Leerink Partnrs boosted their Q2 2024 EPS estimates for Pfizer in a report issued on Thursday, May 2nd. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will earn $0.48 per share for the quarter, up from their prior forecast of $0.41. The consensus estimate for Pfizer’s current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Pfizer’s Q3 2024 earnings at $0.61 EPS, Q4 2024 earnings at $0.72 EPS, FY2024 earnings at $2.63 EPS, FY2026 earnings at $2.97 EPS and FY2027 earnings at $3.05 EPS.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the business posted $1.23 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis.

Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday. Guggenheim began coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Finally, Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $36.00.

Pfizer Trading Up 0.4 %

Shares of PFE opened at $27.81 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer has a 52-week low of $25.20 and a 52-week high of $40.37. The firm has a market cap of $157.48 billion, a price-to-earnings ratio of -463.42, a PEG ratio of 1.19 and a beta of 0.63. The business’s fifty day moving average is $26.88 and its 200-day moving average is $28.16.

Institutional Trading of Pfizer

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PFE. Briaud Financial Planning Inc acquired a new position in Pfizer in the third quarter valued at approximately $30,000. GoalVest Advisory LLC lifted its stake in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Creekmur Asset Management LLC bought a new position in Pfizer in the 4th quarter valued at about $32,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. bought a new stake in Pfizer during the third quarter worth $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.04%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is presently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.